Quiz: SGLT2 Inhibitors in the Management of Feline Diabetes

Sponsored by Elanco

Veterinarians have long relied on insulin injections to manage feline diabetes mellitus. Although insulin injections still play a key role, the advent of new therapies, such as sodium-glucose cotransporter-2 (SGLT2) inhibitors, offers veterinarians new options in the management of this condition.

How familiar are you with the use of SGLT2 inhibitors in the management of feline diabetes? Test your knowledge with this quiz.

INDICATION

Bexacat is indicated to improve glycemic control in otherwise healthy cats with diabetes mellitus not previously treated with insulin.

IMPORTANT SAFETY INFORMATION

Before using Bexacat, you must read the entire package insert, including the boxed warning. Cats treated with Bexacat may be at an increased risk for conditions called diabetic ketoacidosis or euglycemic diabetic ketoacidosis, both of which may result in death. It is critical that cats taking Bexacat be examined by a veterinarian promptly if sudden decreases in appetite or water consumption occur, or if weight loss, tiredness, vomiting, diarrhea, or weakness are seen. Discontinue Bexacat and call your veterinarian immediately if any of these occur as they could be signs of diabetic ketoacidosis or euglycemic diabetic ketoacidosis. Before giving Bexacat, be sure to talk with your veterinarian about any past illnesses your cat has had including if your cat has ever been on insulin, as cats that have been treated with insulin should not receive Bexacat. Do not use Bexacat if your cat has experienced pancreatitis, liver disease or reduced kidney function as serious side effects may occur. Bexacat is available by veterinary prescription only. Not for human use. Keep out of reach of children. Contact a physician immediately if swallowed accidentally.

Bexacat, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. PM-US-24-1756